TY - JOUR
T1 - A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk
AU - Endogenous Hormones Nutritional Biomarkers and Prostate Cancer Collaborative Group
AU - Travis, Ruth C.
AU - Appleby, Paul N.
AU - Martin, Richard M.
AU - Holly, Jeff M.P.
AU - Albanes, Demetrius
AU - Black, Amanda
AU - Bueno-De-Mesquita, H. Bas
AU - Chan, June M.
AU - Chen, Chu
AU - Chirlaque, Maria Dolores
AU - Cook, Michael B.
AU - Deschasaux, Mélanie
AU - Donovan, Jenny L.
AU - Ferrucci, Luigi
AU - Galan, Pilar
AU - Giles, Graham G.
AU - Giovannucci, Edward L.
AU - Gunter, Marc J.
AU - Habel, Laurel A.
AU - Hamdy, Freddie C.
AU - Helzlsouer, Kathy J.
AU - Hercberg, Serge
AU - Hoover, Robert N.
AU - Janssen, Joseph A.M.J.L.
AU - Kaaks, Rudolf
AU - Kubo, Tatsuhiko
AU - Le Marchand, Loic
AU - Metter, E. Jeffrey
AU - Mikami, Kazuya
AU - Morris, Joan K.
AU - Neal, David E.
AU - Neuhouser, Marian L.
AU - Ozasa, Kotaro
AU - Palli, Domenico
AU - Platz, Elizabeth A.
AU - Pollak, Michael N.
AU - Price, Alison J.
AU - Roobol, Monique J.
AU - Schaefer, Catherine
AU - Schenk, Jeannette M.
AU - Severi, Gianluca
AU - Stampfer, Meir J.
AU - Stattin, Pär
AU - Tamakoshi, Akiko
AU - Tangen, Catherine M.
AU - Touvier, Mathilde
AU - Wald, Nicholas J.
AU - Weiss, Noel S.
AU - Ziegler, Regina G.
AU - Key, Timothy J.
N1 - Funding Information:
Centralized pooling, checking, and data analysis were supported by Cancer Research UK grants C8221/A19170 and C570/A11691. Details of funding for the original studies are in the relevant publications. In summary, the funding provided to the collaborating studies was as follows: ATBC: Intramural Research Program of the NIH and the NCI. BLSA: Intramural Research Program, National Institute on Aging, NIH. CHS: This research was supported by grant R01 CA85064 from the NCI and contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant U01HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHSNHLBI. org. EPIC-Greece: the Hellenic Health Foundation. EPIC-Italy: Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy. MORGEN-EPIC cohort of the EPIC Bilthoven centre: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), Statistics Netherlands (the Netherlands). ERSPC: Erasmus MC. HPFS: Supported by grant CA133891 and CA55075 from the NCI,NIH. Also supported in part by a grant to Michael Pollak from the Canadian Cancer Society Research Institute. MCSS: MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. MEC: NCI grants P01 CA 33619, R37 CA 54281, and 1-UM1-CA164973. PCPT: NCI, NIH, CA37429 and P01 CA108964. ProtecT: funded through the NIHR Health Technology Assessment Programme (projects 96/20/06, 96/20/99, www.hta/1230), the authors would like to acknowledge the provision of additional epidemiologic data by the NHS R&D Directorate-supported Prodigal study, the ProMPT (Prostate Mechanisms of Progression and Treatment, grant code G0500966/75466) collaboration, which has funded tissue and urine collections, and is supported by theNational Cancer Research Institute (NCRI) formed by the Department of Health, the Medical Research Council and Cancer Research UK. The funding for IGF assays was supported by Cancer Research UK Project grant (C18281/A7062). These collaborations are supported by the University of Cambridge Cancer Research, UK, and the National Institute for Health Research- funded Cambridge Bio-medical Research Centre, Cambridge, United Kingdom. The MRC/the University of Bristol Integrative Epidemiology Unit (IEU) is supported by the MRC and the University of Bristol. The Bristol Nutrition Biomedical Research Unit is funded by the National Institute forHealth Research and is a partnership between University Hospitals Bristol NHS Trust and the University of Bristol. ProtecT. SU.VI.MAX: support from the Direction G en erale de la Sant e (French Ministry of Health) for laboratory assays.
Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/4/15
Y1 - 2016/4/15
N2 - The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.
AB - The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.
UR - http://www.scopus.com/inward/record.url?scp=84969972281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969972281&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-15-1551
DO - 10.1158/0008-5472.CAN-15-1551
M3 - Article
C2 - 26921328
AN - SCOPUS:84969972281
SN - 0008-5472
VL - 76
SP - 2288
EP - 2300
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -